Case: 4:12-cv CAS Doc. #: 1-1 Filed: 09/28/12 Page: 1 of 22 PageID #: 10 INDEX OF EXHIBITS TO NOTICE OF REMOVAL

Similar documents
Case 3:16-cv Document 1 Filed 07/25/16 Page 1 of 39 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY TRENTON DIVISION

Case 3:17-cv Document 1 Filed 10/20/17 Page 1 of 40 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

Case 4:18-cv JAS Document 1 Filed 03/01/18 Page 1 of 45 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF ARIZONA

Case 3:16-cv Document 1 Filed 09/09/16 Page 1 of 41 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY TRENTON DIVISION

Case 3:17-cv Document 1 Filed 06/02/17 Page 1 of 46 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN THE UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF ALABAMA SOUTHERN DIVISION

Case 2:12-cv Document 1 Filed 06/08/12 Page 1 of 11 PageID #: 1

Case 2:15-cv Document 1 Filed 12/14/15 Page 1 of 49 PageID 1 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TENNESSEE

Case 8:13-cv CJC-JPR Document 1 Filed 08/15/13 Page 1 of 29 Page ID #:1

Case 1:18-cv Document 1 Filed 08/09/18 Page 1 of 47 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

2:14-cv RMG Date Filed 02/25/14 Entry Number 1 Page 1 of 19 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO

Case: 5:18-cv KKC Doc #: 1 Filed: 08/22/18 Page: 1 of 31 - Page ID#: 1

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY CAMDEN VICINAGE ) ) ) ) ) ) ) ) ) ) ) ) ) In re: Forest Research Institute Cases

Case 3:15-cv SMY-DGW Document 1 Filed 10/28/15 Page 1 of 46 Page ID #1

Jury Trial Demanded. Bayer Pharmaceuticals Corporation, Bayer Healthcare Pharmaceuticals, Inc., Plaintiff,

Case 1:15-cv Document 1 Filed 07/24/15 Page 1 of 32

Case 1:16-cv Document 1 Filed 08/23/16 Page 1 of 40 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

Case 1:18-cv Document 1 Filed 03/26/18 Page 1 of 27 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

IN THE UNITED STATES DISTRICT COURT EASTERN DISTRICT OF TENNESSEE GREENEVILLE DIVISION

Case 1:18-cv Document 1 Filed 09/06/18 Page 1 of 49 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

) ) ) ) ) ) ) ) ) COMPLAINT COMMON ALLEGATIONS. REED (Spouse), at all relevant times, were residents of the State of New York.

Case 1:15-cv Document 1 Filed 07/28/15 Page 1 of 38 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF ALABAMA

Case 1:18-cv Document 1 Filed 01/12/18 Page 1 of 33 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY CAMDEN DIVISION

Case 0:17-cv WPD Document 1 Entered on FLSD Docket 10/13/2017 Page 1 of 15 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA CASE NO.

Case 2:17-cv Document 1 Filed 11/14/17 Page 1 of 23 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF LOUISIANA COMPLAINT

IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF TEXAS GALVESTON DIVISION

Plaintiff, Deborah Fellner, by and through her counsel, Eichen Levinson & Crutchlow, LLP, hereby makes this claim against the Defendant as follows:

Case 4:17-cv Document 1 Filed in TXSD on 02/01/17 Page 1 of 25 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF TEXAS. Case No.

Case: 3:15-cv JJH Doc #: 1 Filed: 03/02/15 1 of 33. PageID #: 1 IN THE U.S. DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO WESTERN DIVISION

Case 2:13-cv BCW Document 1 Filed 07/01/13 Page 1 of 37. Plaintiffs, ) Defendants.

FILED 2017 Aug-15 AM 11:59 U.S. DISTRICT COURT N.D. OF ALABAMA

Case 5:17-cv JLH Document 1 Filed 07/31/17 Page 1 of 39

IN THE CIRCUIT COURT FOR AUTAUGA COUNTY, ALABAMA

ALICE WATTS, IN THE DISTRICT COURT OF. Plaintiff, JUDICIAL DISTRICT COURT PLAINTIFF S ORIGINAL PETITION

Case 2:12-cv JRG-RSP Document 1 Filed 08/02/12 Page 1 of 6 PageID #: 1

Case 3:16-cv SDD-EWD Document 1 05/10/16 Page 1 of 50 UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF LOUISIANA

Case 3:10-cv B Document 1 Filed 09/10/10 Page 1 of 6 PageID 1 UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

IN THE CIRCUIT COURT FOR THE SEVENTEENTH JUDICIAL CIRCUIT IN AND FOR BROWARD COUNTY, FLORIDA CIVIL DIVISION. ClassAction.

Case 1:10-cv LJO-SKO Document 1 Filed 07/20/10 Page 1 of 21

CC A CAUSE NO. STEVEN AKIN, IN COUNTY COURT

Case3:09-cv WHA Document48 Filed04/05/12 Page1 of 21

Case 1:13-cv Document 1 Filed 02/11/13 Page 1 of 49 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF NEW YORK

Case 3:13-cv GPM-PMF Document 5 Filed 02/14/13 Page 1 of 15 Page ID #24 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF ILLINOIS

IN THE UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF GEORGIA ATHENS DIVISION

Case 1:09-cv LRR Document 1 Filed 12/28/09 Page 1 of 23

IN THE CIRCUIT COURT OF JACKSON COUNTY, MISSOURI AT INDEPENDENCE

Case 3:17-cv Document 1 Filed 01/13/17 Page 1 of 44 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF OHIO WESTERN DIVISION COMPLAINT FOR DAMAGES WITH JURY DEMAND

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF WISCONSIN (GREEN BAY DIVISION)

CAUSE NO. V. JUDICIAL DISTRICT DEFENDANTS. TARRANT COUNTY, TEXAS PLAINTIFFS ORIGINAL PETITION NOW COMES SHERRY REYNOLDS, BRANDON REYNOLDS, KATY

2:14-cv RMG Date Filed 12/23/14 Entry Number 1 Page 1 of 26

12 CIV VI 1 ti,t. Al JADE BYINGTON and 1. particularly heart defects, and fetal death.

Case 1:16-cv SEB-DML Document 1 Filed 09/09/16 Page 1 of 36 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF INDIANA

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF FLORIDA

Case 2:13-cv SVW-MAN Document 1 Filed 04/17/13 Page 1 of 32 Page ID #:15

I. DISCOVERY CONTROL PLAN

Case 9:16-cv KLR Document 1 Entered on FLSD Docket 01/19/2016 Page 1 of 32

Case 3:17-cv Document 1 Filed 11/10/17 Page 1 of 54 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

Case 2:13-cv KOB Document 1 Filed 02/05/13 Page 1 of 14 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ALABAMA SOUTHERN DIVISION

IN THE CIRCUIT COURT OF CLAY COUNTY, LIBERTY, MISSOURI. Case No. Division

UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK

vs. and MOTION TO AUTHORIZE THE BRINGING OF A CLASS ACTION AND TO ASCRIBE THE STATUS OF REPRESENTATIVE (Art C.C.P.

Case 5:17-cv C Document 1 Filed 07/06/17 Page 1 of 33 PageID 1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF TEXAS LUBBOCK DIVISION

Case 2:15-cv CMR Document 1 Filed 03/09/15 Page 1 of 37 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA

wrongful conduct in connection with the design, development, manufacture, testing, packaging,

COMPLAINT. COMES NOW the Plaintiffs, Christopher Cooper and Shelley Smith, by and through

Case 2:19-cv Document 1 Filed 01/04/19 Page 1 of 36 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Case 1:18-cv ECF No. 1 filed 06/20/18 PageID.1 Page 1 of 8

Case 3:18-cv JSC Document 1 Filed 05/02/18 Page 1 of 11

Case3:14-cv Document1 Filed08/06/14 Page1 of 27

FILED 2015 Aug-03 PM 04:42 U.S. DISTRICT COURT N.D. OF ALABAMA

Case 1:18-cv PLM-PJG ECF No. 1 filed 09/20/18 PageID.1 Page 1 of 9 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION

Case: 4:17-cv AGF Doc. #: 1 Filed: 01/23/17 Page: 1 of 6 PageID #: 1

Case 2:16-cv Document 1 Filed 11/10/16 Page 1 of 18

Case 2:18-cv DMG-SK Document 1-2 Filed 08/09/18 Page 2 of 17 Page ID #:11

Case 3:16-cv Document 1 Filed 08/02/16 Page 1 of 31 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Case: 4:17-cv AGF Doc. #: 1 Filed: 04/11/17 Page: 1 of 21 PageID #: 1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MISSOURI EASTERN DIVISION

13 CV 1 I 03, -against- Plaintiffs, Plaintiffs, JULIE CANTOR MILLER and JONATHAN MILLER (referred

Case: 4:18-cv JAR Doc. #: 1-1 Filed: 02/20/18 Page: 1 of 22 PageID #: 7. Exhibit A - Pleadings Served on Apple

Case 7:18-cv Document 1 Filed 01/12/18 Page 1 of 15 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

Case 4:16-cv LLP Document 1 Filed 12/23/16 Page 1 of 25 PageID #: 1 UNITED STATES DISTRICT COURT DISTRICT OF SOUTH DAKOTA SOUTHERN DIVISION

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF GEORGIA ATLANTA DIVISION

3:18-cv MGL Date Filed 07/31/18 Entry Number 1 Page 1 of 14 IN THE UNITED STATES DISTRICT COURT DISTRICT OF SOUTH CAROLINA COLUMBIA DIVISION

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF ILLINOIS. Plaintiff, Complaint & Jury Demand PLAINTIFF S ORIGINAL COMPLAINT

promoting, marketing, distribution, labeling, and/or sale of sildenafil citrate tablets sold under the

Case 3:10-cv REP Document 52 Filed 12/09/10 Page 1 of 17

Case 3:18-cv AET-LHG Document 1 Filed 10/11/18 Page 1 of 37 PageID: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY. v.

Case 4:15-cv RAL Document 1 Filed 12/07/15 Page 1 of 35 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF SOUTH DAKOTA

For Preview Only - Please Do Not Copy

Case 6:19-cv ADA-JCM Document 1 Filed 01/22/19 Page 1 of 13 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS WACO DIVISION

Case 3:16-cv Document 1 Filed 05/03/16 Page 1 of 19 Page ID #1 IN THE UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF ILLINOIS

Case 1:17-cv Document 1 Filed 04/14/17 Page 1 of 24 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

Case 1:17-cv BLW Document 1 Filed 02/17/17 Page 1 of 27

UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA ALAN GRABISCH, Individually and on Behalf of All Others Similarly Situated, Plaintiff,

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) Case No. Plaintiff, DRAFT. Defendants. CLASS ACTION COMPLAINT

Case 5:15-cv BLF Document 1 Filed 11/05/15 Page 1 of 18

Courthouse News Service

Case: 3:11-cv TMR Doc #: 1 Filed: 11/07/11 Page: 1 of 13 PAGEID #: 1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF OHIO WESTERN DIVISION

IN THE CIRCUIT COURT OF THE CITY OF ST. LOUIS STATE OF MISSOURI

Case 0:17-cv XXXX Document 1 Entered on FLSD Docket 01/13/2017 Page 1 of 12

Transcription:

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 1 of 22 PageID #: 10 INDEX OF EXHIBITS TO NOTICE OF REMOVAL Exhibit Description 1 First Amended Petition for Damages 2 Process, Pleadings, orders, other documents on file in state court 3 Abbott Laboratories, Inc. Certificate of Good Standing

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 2 of 22 PageID #: 11 EXHIBIT 1

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 3 of 22 PageID #: 12 IN THE CIRCUIT COURT OF THE CITY OF S, STATE OF MISSOURI, a minor, and THOMAS AND BETH FORBES, individually and as Next Friends of B F Plaintiffs, ) ) V. ) ) ABBOTT LABORATORIES, INC., ) Serve Registered Agent: ) The Corporation Company ) 120 South Central Avenue ) Clayton, Missouri 63105 ) ) and ) ) INTEGRITY, INC., D/B/A THE MEDICINE ) SHOPPE ) Serve Registered Agent: ) Alan P. Walters ) 228 Main Street ) St. Charles, Missouri 63301 ) ) Defendants. ) ) ) ) ) J. 2 I 221113 JUDICIAL CIRCUIT CIRCUIT CLERK'S OFFICE BY DEPUTY Cause No. 1222 CC 09115 Division No. 1 FIRST AMENDED PETITION FOR DAMAGES COUNT I - STRICT LIABILITY - FAILURE TO WARN COME NOW plaintiffs BE F and as Next Friends of BE F, a minor, and Thomas and Beth Forbes, Individually, and for their cause of action against defendant Abbott Laboratories, Inc. and defendant Integrity, Inc., d/b/a/ The Medicine Shoppe, state as follows: 1. Plaintiffs are citizens and residents of the Si ate of Missouri. Plaintiff BE F is a minor and is represented in this action by his parents and next friends Beth and Thomas Forbes. 2. Defendant Abbott Laboratories, Inc. (hereinafter "Abbott") is and was at all

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 4 of 22 PageID #: 13 relevant times a corporation organized and existing under the laws of the State of Illinois, with its principal place of business and its headquarters in the State of Illinois. 3. At all relevant times, Abbott engaged in the business of designing, licensing, manufacturing, testing, advertising, warranting, distributing, supplying, selling, and introducing into the stream of commerce a drug compound known as -"divalproex sodium," "valproic acid," or "valproate," which Abbott has sometimes marketed under brand names such as "Depakote," "Depakote ER," "Depakene," and "Depacon," all in the City of St. Louis and State of Missouri, and on a substantial and continuous basis. For purposes of this Petition, these various forms and names of the drug compound will all be referred to by their most common brand name, "Depakote." 4. Defendant Integrity, Inc., d/b/a/ The Medicine Shoppe is a pharmacy which distributed on behalf of defendant Abbott and sold in the State of Missouri to Beth and Thomas Forbes the Depakote that caused plaintiff BE F injuries and the damages alleged in this case. 5. Defendant Integrity, Inc., d/b/a/ The Medicine Shoppe (hereinafter "The Medicine Shoppe") is and was at all relevant times a corporation organized and existing under the laws of the State of Missouri with its headquarters and principal place of business in the State of Missouri and with its registered agent located in the State of Missouri. 6. Venue for this action is proper in this Court pursuant to 508.010.4 RSMo., in that plaintiff Brett Forbes was first injured by the wrongful conduct alleged herein in the City of St. Louis, State of Missouri-. 7. Jurisdiction is proper in this Court and this action may not be removed based on 2

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 5 of 22 PageID #: 14 diversity of citizenship because plaintiffs and defendant The Medicine Shoppe are citizens of the State of Missouri. 8. In approximately 1978; after Abbott received approval to market Depakote in the United States for treatment of certain forms of epilepsy, Abbott began marketing and placing Depakote into the stream of commerce throughout the United States and promoting Depakote as an effective anti-epileptic drug. 9. The primary compound in Depakote, valproic acid, causes an unreasonably high incidence of severe birth defects if taken during the first trimester of pregnancy, especially during the first twenty-eight days of gestation, when neural tube closure and other critical midline formations are taking place in the cellular structure of the developing embryo. I 0. Among the severe birth defects known to result directly from first-trimester exposure to Depakote are, either singly or in some combination with each other, spina bifida, cleft palate, cleft lip, limb and digital deformities, facial dysmorphism, mental development delays, genitourinary maloformations, and heart defects. 11. Since the mid-1990s, Abbott has promoted, marketed, distributed, and sold Depakote for unapproved, off-label uses such as for treatment of mild depression, the depressive stage of bi-polar disorder, and chronic pain conditions such as migraine headaches. 12. Abbott has admitted to criminal misbranding in connection with this off-label use in violation of the Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq., which included paying doctors and pharmacists illegal kickbacks to induce them to promote Depakote for unapproved, off-label uses. 13. In or about April 2003, plaintiff Beth Forbes was prescribed and began taking 3

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 6 of 22 PageID #: 15 Depakote for depression. 14. During the time plaintiff Beth Forbes was taking Depakote, she unknowingly became pregnant. 15. On 2005, plaintiff Beth Forbes gave birth to plaintiff B F at Barnes Hospital in the City of St. Louis, Missouri, after which time BE F= was diagnosed with spina bifida. 16. At the time defendants Abbott and The Medicine Shoppe marketed, distributed, and sold the Depakote at issue in this case, it was unreasonably dangerous when put to a reasonably anticipated use without knowledge of its characteristics. 17. Defendants Abbott and The Medicine Shoppe did not give an adequate warning of the dangers. 18. The Depakote at issue here was used in a manner reasonably anticipated by Abbott and The Medicine Shoppe. 19. As a direct and proximate result of the Depakote being sold without an adequate warning, plaintiff BE F= sustained serious and permanent injuries and damages including: (a) (c) (d) (e) Disfigurement; Permanent mental and physical impairment; Numerous painful medical procedures; Conscious physical pain and suffering, mental anguish, distress, embarrassment, and loss of enjoyment of life; The reasonable and necessary expenses for the medical treatment, rendered to plaintiff B F in the past in an amount to be determined; 4

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 7 of 22 PageID #: 16 (i) (g) The reasonable and necessary expenses for the medical treatment, that will be needed by plaintiff BE F in the future; and Future economic damages including lost income, lost earning capacity, and other economic losses in an amount to be determined. 20. As a further direct and proximate result of the Depakote being sold without an adequate warning, plaintiffs Beth and Thomas Forbes have suffered and will continue to suffer the following damages: (a) The reasonable value of BE F 'services; Past and future medical, vocational, educational, and rehabilitative expenses in an amount to be determined. 21. The following conduct on the part of defendants Abbott and The Medicine Shoppe demonstrates their complete indifference to or conscious disregard for the safety of others which warrants the imposition of punitive damages to deter defendants and others similarly situated from like conduct in the future: a. Defendants Abbott and The Medicine Shoppe knew of the unreasonably high risk of birth defects including spina bifida associated with Depakote in early-term pregnancies before it marketed, distributed, and sold the involved in this case. b. Despite its knowledge described in the preceding paragraph, defendants Abbott and The Medicine Shoppe affirmatively minimized the aforementioned risk through its marketing and product labeling and package inserts. WHEREFORE, plaintiffs pray judgment against defendant Abbott and defendant The Medicine Shoppe in an amount in excess of Twenty-Five Thousand Dollars ($25,000.00), 5

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 8 of 22 PageID #: 17 exclusive of interest and costs, for their costs, for punitive damages, and for such other and further relief as the Court may deem proper in the premises. COUNT II STRICT LIABILITY DESIGN DEFECT COME NOW plaintiffs and for Count II of their Petition against defendant Abbott and defendant The Medicine Shoppe, state as follows: 1. Plaintiffs incorporate by reference the allegations set forth above in this Petition, the same as if fully set forth herein. 2. Defendants sold in the course of their business the Depakote at issue in this case. 3. At the time the defendants sold the Depakote, it was in a defective condition unreasonably dangerous when put to a reasonably anticipated use. 4. The Depakote was used in a manner reasonably anticipated by defendants. 5. As a direct and proximate result of the Depakote being in a defective and unreasonably dangerous condition when sold, plaintiff BE F sustained serious and permanent injuries and damages including: (a) Disfigurement; - (c) (d) (e) Permanent mental and physical impairment; Numerous painful medical procedures; Conscious physical pain and suffering, mental anguish, distress, embarrassment, and loss of enjoyment of life; The reasonable and necessary expenses for the medical treatment, rendered to plaintiff BE F= in the past in an amount to be determined; 6

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 9 of 22 PageID #: 18 (f) (g) The reasonable and necessary expenses for the medical treatment, that will be needed by plaintiff BE F in the future; and Future economic damages including lost income, lost earning capacity, and other economic losses in an amount to be determined. 6. As a further direct and proximate result of the Depakote being in a defective and unreasonably dangerous condition when sold, plaintiffs Beth and Thomas Forbes have suffered and will continue to suffer the following damages: (a) The reasonable value of BE F services; Past and future medical, vocational, educational, and rehabilitative expenses in an amount to be determined. 7. The following conduct on the part of defendants demonstrates their complete indifference to or conscious disregard for the safety of others which warrants the imposition of punitive damages to deter defendants and others similarly situated from like conduct in the future: a. Defendants knew of the unreasonably high risk of birth defects including spina bifida associated with Depakote in early-term pregnancies before it marketed, distributed, and sold the involved in this case. b. Despite its knowledge described in the preceding paragraph, defendants affirmatively minimized the aforementioned risk through its marketing and product labeling and package inserts. WHEREFORE, plaintiffs pray judgment against defendant Abbott and defendant The Medicine Shoppe in an amount in excess of Twenty-Five Thousand Dollars ($25,000.00), 7

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 10 of 22 PageID #: 19 exclusive of interest and costs, for their costs, for punitive damages, and for such other and further relief as the Court may deem proper in the premises. COUNT III NEGLIGENCE FAILURE TO WARN DESIGN DEFECT COME NOW plaintiffs, and for Count III of their Petition against defendant Abbott, state as follows: 1. Plaintiffs incorporate by reference the allegations set forth in Counts I and II of this Petition, the same as if fully set forth herein. 2. Defendant Abbott failed to use ordinary care in one or more of the following respects in connection with its development, design, formulation, research, research funding, testing, product literature, product packaging, and purported product warnings: a. By failing to provide plaintiffs with adequate warnings of the unreasonably high risk of birth defects associated with Depakote use during the first trimester of a pregnancy; b. By failing to properly market the Depakote; c. By marketing Depakote for use beyond its original anti-epileptic purposes. 3. As a direct result of defendant Abbott's failure in one of more of the foregoing respects, plaintiff BE F sustained serious and permanent injuries and damages including: (a) (c) Disfigurement; Permanent mental and physical impairment; Numerous painful medical procedures; 8

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 11 of 22 PageID #: 20 (d) (e) Conscious physical pain and suffering, mental anguish, distress, embarrassment, and loss of enjoyment of life; The reasonable and necessary expenses for the medical treatment, rendered to plaintiff BE F in the past in an amount to be determined; (0 The reasonable and necessary expenses for the medical treatment, that will be needed by plaintiff BE F in the future; and (g) Future economic damages including lost income, lost earning capacity, and other economic losses in an amount to be determined. 4. As a further direct and proximate result of defendant Abbott's failure in one of more of the foregoing respects, plaintiffs Beth and Thomas Forbes have suffered and will continue to suffer the following damages: (a) The reasonable value of BE F services; Past and future medical, vocational, educational, and rehabilitative expenses in an amount to be determined. 5. The following conduct on the part of defendant Abbott demonstrates Abbott's complete indifference to or conscious disregard for the safety of others which warrants the imposition of punitive damages to deter defendant Abbott h.nd others similarly situated from like conduct in the future: a. Defendant Abbott knew of the unreasonably high risk of birth defects including spina bifida associated with Depakote in early-term pregnancies before it marketed, distributed, and sold the involved in this case. b. Despite its knowledge described in the preceding paragraph, defendant Abbott affirmatively minimized the aforementioned risk through its marketing and 9

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 12 of 22 PageID #: 21 product labeling and package inserts. WHEREFORE, plaintiffs pray judgment against defendant Abbott in an amount in excess of Twenty-Five Thousand Dollars ($25,000.00), exclusive of interest and costs, for their costs, for punitive damages, and for such other and further relief as the Court may deem proper in the premises. COUNT IV-NEGLIGENT PHARMACO-VIGILANCE COME NOW plaintiffs and for Count IV of their Petition against defendant Abbott, state as follows: 1. Plaintiffs hereby incorporate by reference each of the preceding paragraphs as if fully set forth herein. 2. Abbott has an ongoing duty of phamiaco-vigilance. As part of this duty, Abbott is required to continually monitor, test and analyze data regarding the safety, efficacy and prescribing practices of their marketed drugs, including Depakote. Abbott continually receives reports from their own clinical trials, practicing physicians, individual patients and regulatory authorities of adverse events that occur in patients taking Depakote and their other marketed drugs. Furthermore, Abbott continues to conduct clinical trials for their marketed drugs long after the drug is approved for use. Abbott has a duty to inform doctors, regulatory agencies and the public of new safety and efficacy information they learn, or should have learned, about their marketed drugs once that information becomes available to Abbott, whether through Abbott's clinical trials, other outside sources, or phannaco-vigilance activities. Specifically, when Abbott learns, or should have learned, of new safety information associated with its marketed drugs, Abbott has a duty to promptly disseminate that data to the public. Abbott also has a duty to 10

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 13 of 22 PageID #: 22 monitor epidemiological and phatmaco-vigilance data regarding its marketed drugs and promptly report any safety concerns that arise through epidemiologic study or data. 3. Abbott breached this duty with respect to Plaintiffs. Abbott, through various sources, including but not limited to, clinical trials and other adverse event reports, learned that there was a substantial risk of birth defects associated with. Depakote use during pregnancy and failed to inform doctors, regulatory agencies, and the public of this risk. Abbott had the means and the resources to perform their pharmaco-vigilance duties for the entire time Depakote has been on the market in the United States. 4. As a direct and proximate result of defendant Abbott's breach of its pharmacovigilance duty, plaintiff BE IM sustained serious and permanent injuries and damages including: (a) (c) (d) (e) Disfigurement; Permanent mental and physical impairment; Numerous painful medical procedures; Conscious physical pain and suffering, mental anguish, distress, embarrassment, and loss of enjoyment of life; The reasonable and necessary expenses for the medical treatment, rendered to plaintiff BE F= in the past in an amount to be determined; (0 The reasonable and necessary expenses for the medical treatment, that will be needed by plaintiff BE F in the future; and (g) Future economic damages including lost income, lost earning capacity, and other economic losses in an amount to be determined. 5. As a further direct and proximate result of defendant Abbott's breach of its 11

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 14 of 22 PageID #: 23 phannaco-vigilance duty, plaintiffs Beth and Thomas Forbes have suffered and will continue to suffer the following damages: (a) The reasonable value of 11 F services; Past and future medical, vocational, educational, and rehabilitative expenses in an amount to be determined. 6. The foregoing conduct on the part of defendant Abbott demonstrates Abbott's complete indifference to or conscious disregard for the safety of others which warrants the imposition of punitive damages to deter defendant Abbott and others similarly situated from like conduct in the future. WHEREFORE, plaintiffs pray judgment against defendant Abbott in an amount in excess of Twenty-Five Thousand Dollars ($25,000.00), exclusive of interest and costs, for their costs, for punitive damages, and for such other and further relief as the Court may deem proper in the premises. COUNT V-BREACH OF EXPRESS WARRANTY COME NOW plaintiffs and for Count V of their Petition against defendant Abbott, state as follows: 1. Plaintiffs hereby incorporate by reference each of the preceding paragraphs as if fully set forth herein. 2. At all times herein mentioned, Abbott, by directly and indirectly advertising, marketing, and promoting Depakote for the treatment of women during child-bearing years, including during pregnancy, and by placing this drug in the stream of commerce knowing that 12

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 15 of 22 PageID #: 24 Depakote would be prescribed to pregnant women in reliance upon the representations of Abbott, Abbott expressly warranted to all foreseeable users of the drug, including plaintiff Beth Forbes, that Depakote was safe and effective for the treatment of women during pregnancy and without significant risk to the fetus. 3. Plaintiff Beth Forbes relied upon the aforesaid express warranties by Abbott. 4. The use of Depakote by plaintiff Beth Forbes was consistent with the purposes for which Abbott directly and indirectly advertised, marketed and promoted Depakote, her use of Depakote was reasonably contemplated, intended, and foreseen by Abbott at the time of the distribution and sale of Depakote by Abbott, and, therefore, her use of Depakote was within the scope of the above-described express warranties. 5. Abbott breached the aforesaid express warranties because Depakote was not safe for the treatment of women during pregnancy. Instead, Depakote exposed the developing fetus to a significant risk of serious injury. 6. As a direct and proximate result of defendant Abbott's breach of its aforesaid express warranties, plaintiff BE F sustained serious and permanent injuries and damages including: (a) (c) (d) (e) Disfigurement; Permanent mental and physical impairment; Numerous painful medical procedures; Conscious physical pain and suffering, mental anguish, distress, embarrassment, and loss of enjoyment of life; The reasonable and necessary expenses for the medical treatment, rendered to plaintiff BE F in the past in au amount to be 13

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 16 of 22 PageID #: 25 determined; The reasonable and necessary expenses for the medical treatment, that will be needed by plaintiff BE I= in the future; and Future economic damages including lost income, lost earning capacity, and other economic losses in an amount to be determined. 7. As a further direct and proximate result of defendant Abbott's breach of its aforesaid express warranties, plaintiffs Beth and Thomas Forbes have suffered and will continue to suffer the following damages: (a) The reasonable value of BE F services; Past and future medical, vocational, educational, and rehabilitative expenses in an amount to be determined. WHEREFORE, Plaintiffs pray for judgment against the Abbott in an amount in excess of Twenty-Five Thousand Dollars ($25,000.00) exclusive of costs, their costs expended herein, and for such further and other relief as the Court deems just and proper. COUNT VI BREACH OF IMPLIED WARRANTY OF MERCHANTABILITY COME NOW plaintiffs, and for Count VI of their Petition against defendant Abbott and defendant The Medicine Shoppe, state as follows: 1. Plaintiffs incorporate by reference the allegations set forth in the preceding paragraphs of this Petition, the same as if fully set forth herein. 2. When defendants sold the Depakote, it was not fit for one of its ordinary purposes which included the treatment of depression in women of child-bearing years. 3. Plaintiff Beth Forbes used the Depakote for such purpose. 14

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 17 of 22 PageID #: 26 4. Defendants have been given notice that the product was not fit for such purposes. 5. As a direct result of the Depakote being unlit for one or more of its purposes, plaintiff BE F (a) (c) (d) (e) sustained serious and permanent injuries and damages including: Disfigurement; Permanent mental and physical impairment; Numerous painful medical procedures; Conscious physical pain and suffering, mental anguish, distress, embarrassment, and loss of enjoyment of life; The reasonable and necessary expenses for the medical treatment, rendered to plaintiff BE F in the past in an amount to be determined; (0 The reasonable and necessary expenses for the medical treatment, that will be needed by plaintiff BE F in the future; and (g) Future economic damages including lost income, lost earning capacity, and other economic losses in an amount to be determined. 6. As a further direct and proximate result of the Depakote being unfit for one or more of its purposes, plaintiffs Beth and Thomas have suffered and will continue to suffer the following damages: (a) The reasonable value of BE F services; Past and future medical, vocational, educational, and rehabilitative expenses in an amount to be determined. 7. The foregoing conduct on the part of defendants demonstrates defendants' complete indifference to or conscious disregard for the safety of others which warrants the imposition of punitive damages to deter defendants and others similarly situated from like 15

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 18 of 22 PageID #: 27 conduct in the future. WHEREFORE, plaintiffs pray judgment against defendant Abbott and defendant The Medicine Shoppe in an amount in excess of Twenty-Five Thousand Dollars ($25,000.00), exclusive of interest and costs, for their costs, for punitive damages, and for such other and further relief as the Court may deem proper in the premises. COUNT VII-FRAUD COME NOW plaintiffs and for Count VII of their Petition against defendant Abbott, state as follows: 1. Plaintiffs hereby incorporate by reference each of the preceding paragraphs as if fully set forth herein. 2. In deciding whether to prescribe a drug, doctors do a risk/benefit assessment in determining which drug to prescribe. Doctors, such as Beth Forbes' doctors and healthcare providers, rely on the information received about Depakote from various sources, such as journal articles, company literature, and discussions with Abbott's sales people. Such information must be accurate and provide an unbiased picture of a drug's safety and efficacy in treating a condition. If the information is false or misleading, the doctor, such as Beth Forbes' doctors and healthcare providers, cannot accurately assess the crucial risk/benefit balance for the patient or exercise professional judgment that is independent. Consequently, the doctor, including Beth Forbes' doctors and health care providers, cannot act in accordance with the professional and fiduciary obligations owed to the patient, nor can the patient, or in this instance Beth Forbes, give informed consent to the treatment. 3. Concealing adverse information and providing inaccurate or biased information 16

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 19 of 22 PageID #: 28 that is material to a prescribing decision misleads the physician and the patient who relies on that physician's professional judgment, as was the case with Beth Forbes and her doctors and healthcare providers. This misleading information, along with omissions of material facts related to Depakote's safety, causes and caused health care providers, patients and the general public to be misled about Depakote's risks and benefits and prevent doctors from making a proper risk/benefit assessment as to the use of Depakote. In flagrant and conscious disregard and indifference, Abbott denied publicly any connection between Depakote and birth defects, and failed to take any measures whatsoever to alert the public, the prescribing physicians, and the patients who take it, of the incipient dangers associated with Depakote. 4. Abbott's advertising program used affirmative misrepresentations and omissions to falsely and deceptively create the image and impression that Depakote was safe for human use; had no known unacceptable, side effects; had fewer side effects than other comparable drugs; was safe for off-label use; and would not interfere with daily life. 5. Abbott purposefully concealed, failed to disclose, misstated, downplayed and understated the health hazards and risks associated with the use of Depakote. Abbott, through promotional literature, deceived potential users and prescribers of said drug by relying on only allegedly positive information, including testimonials from allegedly satisfied users, and manipulating statistics to suggest widespread acceptability, while concealing, misstating and downplaying the known adverse and serious health effects. Abbott falsely and deceptively kept relevant information from potential Depakote users and minimized prescriber concerns regarding the safety and efficacy of Depakote. 6. In particular, in the materials disseminated by Abbott, Abbott falsely and 17

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 20 of 22 PageID #: 29 deceptively misrepresented or omitted a number of material facts regarding the previously stated allegations. 7. When said representations and/or omissions were made by Abbott, Abbott knew those representations and/or omissions to be false, or willfully, wantonly and recklessly disregarded whether the representations and/or omissions were true. These representations and/or omissions were made by Abbott with the intent of defrauding and deceiving the public in general and the medical community, and with the intent of inducing the public to take Depakote and the medical community to recommend, prescribe, and dispense Depakote for use with women during pregnancy. 8. The aforementioned misrepresentations by Abbott were reasonably relied upon by plaintiff Beth Forbes and/or her prescribing physician to their detriment. 9. As a direct and proximate result of defendant Abbott's breach of its aforesaid express warranties, plaintiff BE F sustained serious and permanent injuries and damages including: (a) (c) (d) (e) Disfigurement; Permanent mental and physical impairment; Numerous painful medical procedures; Conscious physical pain and suffering, mental anguish, distress, embarrassment, and loss of enjoyment of life; The reasonable and necessary expenses for the medical treatment, rendered to plaintiff BE FMin the past in an amount to be determined; (0 The reasonable and necessary expenses for the medical treatment, 18

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 21 of 22 PageID #: 30 that will be needed by plaintiff BE F in the future; and (g) Future economic damages including lost income, lost earning capacity, and other economic losses in an amount to be determined. 10. As a further direct and proximate result of defendant Abbott's breach of its aforesaid express warranties, plaintiffs Beth and Thomas Forbes have suffered and will continue to suffer the following damages: (a) The reasonable value of BE F services; Past and future medical, vocational, educational, and rehabilitative expenses in an amount to be determined. 11. The foregoing conduct on the part of defendant Abbott demonstrates its complete indifference to or conscious disregard for the safety of others which warrants the imposition of punitive damages to deter Abbott and others similarly situated from like conduct in the future. WHEREFORE, Plaintiffs pray for judgment against defendant Abbott in an amount in excess of Twenty-Five Thousand Dollars ($25,000.00), exclusive of costs, their costs, punitive damages, and for such further and other relief as the Court deems just and proper. 111411, Respect Sub itted, James wd MO ;',1984 THE JAM N. DOW - AW FIRM 15 North Gore Avenue, Sutie 210 St. Louis, Missouri 63119 Telephone: (314) 961-4442 Facsimile: (314) 961-4452 jim@jimdowdlaw.com KELL LAMPIN, LLC 19

Case: 4:12-cv-01760-CAS Doc. #: 1-1 Filed: 09/28/12 Page: 22 of 22 PageID #: 31 J. Mark Kell #26413 Charles Lampin 5770 Mexico Road St. Peters, Missouri 63376 Telephone: (636) 498-4000 Facsimile: (636) 757-0198 Attorney for Plaintiffs 20